角膜交联核黄素给药频率治疗圆锥角膜与角膜扩张的前瞻性随机试验
前瞻性随机单中心等效性试验纳入510例进展性圆锥角膜或屈光术后角膜扩张患者,一眼随机接受2分钟或5分钟核黄素给药间隔的标准角膜交联。6个月时最大角膜曲率值平均降低在两组间等效(0.97D vs 0.76D,90%CI -0.23至0.66),安全性良好。
要点
- 2分钟与5分钟核黄素给药间隔在6个月时最大角膜曲率值降低等效。
- 两种给药间隔下矫正远视力平均改善0.07 logMAR或3.5个字母。
- 635眼中134眼(21%)视力增加≥2行,32眼(5%)视力下降≥2行。
核心结论
- 两种核黄素给药方案产生的最大角膜曲率值降低等效,且安全性良好。
研究设计与样本
- 前瞻性、随机、单中心等效性试验,纳入进展性圆锥角膜或屈光术后角膜扩张患者510例,每例患者一眼随机接受2分钟或5分钟核黄素给药间隔的标准角膜交联(去除上皮后以3 mW/cm²紫外线照射30分钟),采用区组随机化使两治疗组中圆锥角膜与屈光术后角膜扩张的构成比相当,等效性采用双单侧检验评估,对侧眼207眼接受5分钟给药并纳入安全性分析。
主要发现
- 6个月时最大角膜曲率值较基线的平均降低在2分钟与5分钟核黄素给药间隔组间等效(分别为0.97D和0.76D,治疗差异的90%置信区间为-0.23至0.66,符合方案人群)。
- 两种给药间隔下矫正远视力平均改善均为0.07 logMAR或3.5个字母(6个月时)。
- 6个月检查的635只研究眼和对侧眼中,134眼(21%)矫正远视力增加≥2行,32眼(5%)下降≥2行。
- 3眼(0.4%)发生无菌性浸润,1眼(0.1%)出现上皮愈合延迟伴树枝状改变,3眼(0.4%)出现复发性上皮缺损,3眼(0.4%)接受再次治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate whether the riboflavin dosing frequency affects corneal cross-linking efficacy or safety, given that isotonic riboflavin solution is viscous and each installation coats the corneal surface with a film that absorbs some of the incident ultraviolet A light. DESIGN: Prospective, randomized, single-center equivalence trial. PARTICIPANTS: Patients with progressive keratoconus or ectasia after refractive surgery (n = 510). METHODS: One eye per patient was prospectively randomized to 2-minute or 5-minute riboflavin dosing intervals with standard corneal cross-linking (epithelial removal and 30-minute irradiation with 3 mW/cm2 ultraviolet A light). Block randomization resulted in comparable representation of keratoconus and ectasia after refractive surgery in the 2 treatment arms. Treatment equivalence was assessed using the 2 one-sided test. Fellow eyes (n = 207) were treated with 5-minute dosing and considered in the safety analysis. MAIN OUTCOME MEASURES: The primary hypothesis was equivalent change in the topography-derived maximum keratometry value from baseline to 6 months with 2-minute vs. 5-minute dosing. A ±0.75-diopter margin of equivalence for the treatment difference between dosing regimens was considered clinically relevant. Adverse events and changes from baseline to 6 months in corrected distance visual acuity (CDVA), uncorrected distance visual acuity, and minimum corneal thickness were assessed. RESULTS: The mean reduction in maximum keratometry from baseline was equivalent with 2-minute and 5-minute riboflavin dosing intervals at 6 months (0.97 and 0.76 diopters, respectively; 90% confidence interval for treatment difference, -0.23 to 0.66; per-protocol population). With both dosing intervals, the mean improvement in CDVA was 0.07 logarithm of the minimum angle of resolution or 3.5 letters at 6 months. Of the 635 study and fellow eyes examined at 6 months, 134 (21%) gained and 32 (5%) lost 2 or more lines of CDVA. Three eyes (0.4%) developed sterile infiltrates, 1 (0.1%) had delayed epithelial healing with dendrites, and 3 (0.4%) had recurrent epithelial defects. Three eyes (0.4%) were re-treated. CONCLUSIONS: The 2 riboflavin dosing regimens produced equivalent reduction in the maximum keratometry value, with a favorable safety profile.
引用
- Price MO, Fairchild K, Feng MT, et al. Prospective Randomized Trial of Corneal Cross-linking Riboflavin Dosing Frequencies for Treatment of Keratoconus and Corneal Ectasia. Ophthalmology. 2017. PMID: 29203068. doi:10.1016/j.ophtha.2017.10.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。